Double Blind Randomised Placebo Controlled Evaluation of Single and Multiple Oral Doses of ATX2417 in Man and Effect of Food

Trial Profile

Double Blind Randomised Placebo Controlled Evaluation of Single and Multiple Oral Doses of ATX2417 in Man and Effect of Food

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2016

At a glance

  • Drugs ATX 2417 (Primary)
  • Indications Asthma; Hypersensitivity
  • Focus Adverse reactions; First in man
  • Sponsors Atopix Therapeutics
  • Most Recent Events

    • 12 Jul 2016 Status changed from recruiting to completed.
    • 26 May 2015 According to ClinicalTrials.gov, treatment arms increased from 14 to 18; patient number changed from 56 to 72.
    • 26 May 2015 Planned number of patients changed from 56 to 72 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top